Veterinary Medicine Articles | Ethos Discovery

BEVERLY, Mass. USA – November 1, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics, today announced it has finalized the design of the MiQLab™ Pneumonia Panel for companion animals and completed initial multiplex

Ethos Discovery today announced the launch of a several new clinical trials for dogs with septic peritonitis

Ethos Discovery Announces Multidisciplinary Strategic Research Collaboration to FurtherEthos-PUSH Study Aimed at Finding a Cure for Hemangiosarcoma

Many of the cancers afflicting companion animals also occur in humans, offering the opportunity to improve the lives of animal and human patients by studying cancers and treatments in both species in parallel. Delegates at the workshop included other members of the WSAVA OHC, academics and industry representatives working in cancer research with an emphasis on drug discovery.

Thank you to Frankie’s Friends for their support of our Hemagiosarcoma and Sepsis research programs.

Vuja De Sciences (“Vuja De”), a biotechnology startup dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, DACVIM (Onc), and Dr. Lee Helman, MD, to its Board of Directors.

The Ethos Discovery 2018 Annual Report is available. Although the focus of our scientific agenda has prioritized the delivery of health improvements to veterinary patients, our work has the potential to influence advances to improve health outcomes in human patients with similar conditions.

Ethos Discovery is excited to announce a $5,000 grant received by Citizens Bank in support of the Ethos Discovery Research program.

Ethos Discovery recently announced its plan to deliver curative outcomes for dogs with splenic hemangiosarcoma.

Source: LexaGene Holdings Inc BEVERLY, MA, June 05, 2019 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has placed its first beta prototype into Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn,

Veterinarians have been using polymerase chain reaction for antigen receptor rearrangement (PARR), a readily available molecular assay that helps diagnose some kinds of canine lymphoma, for years.

In a study published in the Journal of Veterinary Internal Medicine (JVIM), Ethos and TGen found that their test, called ePARR, was more than 90 percent accurate among a range of lymphoma sample types. TGen conducted genetic analysis of more than 180 dogs with naturally occurring cancer to confirm if they had lymphoma, and then determine exactly what type of lymphoma, which is a common and aggressive cancer in dogs.